SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ONXX

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (284)4/11/1999 9:39:00 PM
From: scaram(o)uche   of 810
 
[PROC. AMER. ASSOC. CANCER RES. 40, March 1999]
Copyright © 1999 by the American Association for Cancer Research

#2061 Modulation of the immune response to recombinant adenoviruses. Gurnani, M., Shi, B., Zepeda, M.,
and Nielsen, L.L. Tumor Biology and Canji, Schering-Plough Res. Inst., Kenilworth, NJ 07033 and San Diego,
CA 92121.

SCH58500 is a novel therapeutic agent for gene therapy (GT) of cancer consisting of a replication-deficient, type 5
adenovirus (Ad) expressing human p53 tumor suppressor. SCH58500 has efficacy in a wide variety of cancer models
with nonfunctional p53 protein. One aspect of adenovirus-mediated GT which requires further study is the patient's
immune response against the Ad vector. In preclinical models, this is characterized by a rapid cellular response to Ad
administration and a later, neutralizing antibody response. We have previously shown both adenovirus- and
p53-mediated contributions to the activity of SCH58500. Several human tumor xenograft models and one
immune-competent, mouse tumor model were used to evaluate the effects of different immune modulators on cancer
efficacy. In scid-beige mice (defective T, B, and NK cells), anti-tumor efficacy was completely due to p53 expression,
with no Ad component. In tumor-bearing scid mice, the same result was achieved by intravenous anti-NK cell
antibody. These data emphasize the importance of NK cells in the Ad-mediated tumor response. Dexamethasone
(Dex) abrogated the cellular immune response against Ad in immune-competent FVB mice, thereby abolishing tumor
growth suppression caused by Ad after intraperitoneal or intratumoral dosing, but not antibody development.
Cyclophosphamide is the only DNA-damaging drug tested which did not enhance the efficacy of SCH58500 in human
tumor xenograft models. Further, cyclophosphamide neutralized all Ad activity after intraperitoneal dosing of
tumor-bearing FVB mice. These data suggest more complicated interactions between recombinant adenoviruses,
chemotherapy drugs, and the host immune system than previously suspected.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext